Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

Tiffany R. Hodges(University School), Amy B. Heimberger(Northwestern University)

Neuro-Oncology

February 15, 2017

10.1093/neuonc/nox026

Cited by 427

Related Papers

Glioma cancer stem cells induce immunosuppressive macrophages/microglia

|Neuro-Oncology|2010|708

Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype

|JCI Insight|2016|454

Hypoxia Potentiates Glioma-Mediated Immunosuppression

|PLoS ONE|2011|219

Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages

|Neuro-Oncology|2019|165

Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models

|Clinical Cancer Research|2021|134